Synergistic chemsensitization and inhibition of tumor growth and metastasis by the antisense oligodeoxynucleotide targeting clusterin gene in a human bladder cancer model

Clinical Cancer Research

Volumn 7, Issue 12, 2001, Pages 4245-4252

  Miyake, Hideaki ^a,b   Gleave, Martin E ^a,b   Hara, Isao ^c   Kamidono, Sadao ^c  

^a VANCOUVER GENERAL HOSPITAL   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c KOBE UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; CISPLATIN; CLUSTERIN; MESSENGER RNA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLADDER CANCER; CANCER INHIBITION; CANCER MODEL; CONTROLLED STUDY; DRUG POTENTIATION; FEMALE; GENE TARGETING; HUMAN; HUMAN CELL; METASTASIS INHIBITION; MOUSE; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL;

ANIMALS; CLUSTERIN; DRUG SYNERGISM; GENE EXPRESSION REGULATION, NEOPLASTIC; GLYCOPROTEINS; HUMANS; KINETICS; LYMPHATIC METASTASIS; MICE; MICE, NUDE; MODELS, BIOLOGICAL; MOLECULAR CHAPERONES; NEOPLASM PROTEINS; OLIGODEOXYRIBONUCLEOTIDES, ANTISENSE; TRANSCRIPTION, GENETIC; TRANSPLANTATION, HETEROLOGOUS; TUBULIN; TUMOR CELLS, CULTURED; URINARY BLADDER NEOPLASMS;

EID: 0035675829     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Multimodality therapy for the treatment of muscle-invasive bladder cancer
2. Recent advances in bladder cancer chemotherapy
3. Clusterin: Physiologic and pathophysiologic considerations
4. SGP-2 expression as a genetic marker of progressive cellular pathology in experimental hydronephrosis
5. Programmed cell death during regression of the MCF-7 human breast cancer following estrogen ablation
6. Distinct sites of production and deposition of the putative cell death marker clusterin in the human thymus
7. Prevention of cell death induced by tumor necrosis factor α in LNCaP cells by overexpression of sulfated glycoprotein-2 (clusterin)
8. Testosterone-repressed prostate message-2 is an antiapoptotic gene involved in progression to androgen-independence in prostate cancer
9. Acquisition of chemoresistant phenotype by overexpression of the antiapoptotic gene, testosterone-repressed prostate message-2, in prostate cancer xenograft models
10. Antisense TRPM-2 oligodeoxynucleotides chemosensitize human androgen-independent PC-3 prostate cancer cells both in vitro and in vivo
11. Novel therapeutic strategy for advanced prostate cancer using antisense oligodeoxynucleotides targeting antiapoptotic genes up-regulated after androgen withdrawal to delay androgen-independent progression and enhance chemosensitivity
12. Molecular targets for the therapeutic manipulation of apoptosis in bladder cancer
13. Gene therapy of human bladder cancer with adenovirus-mediated antisense basic fibroblast growth factor
14. Basic fibroblast growth factor regulates matrix metallo-proteinases production and in vitro invasiveness in human bladder cancer cell lines
15. Treatment of bladder cancer cells in vitro and in vivo with 2-5A antisense telomerase RNA
16. Calcium ionophore, ionomycin inhibits growth of human bladder cancer cells both in vitro and in vivo with alteration of Bcl-2 and Bax expression levels
17. Synergistic chemosensitization and inhibition of tumor growth and metastasis by adenovirus-mediated p53 gene transfer in human bladder cancer model
18. The state of the art in antisense research
19. Antitumor activity of a phosphorothioate antisense oligodeoxynucleotide targeted against C-raf kinase
20. In vitro and in vivo reversal of multidrug resistance in a human leukemia-resistant cell line by mdr1 antisense oligodeoxynucleotides
21. Antisense Bcl-2 oligodeoxynucleotides inhibit progression to androgen-independence after castration in the Shionogi tumor model
22. Castration-induced up-regulation of insulin-like growth factor binding protein-5 potentiates insulin-like growth factor-I activity and accelerates progression to androgen independence in prostate cancer models
23. Antitumor activity of a C-raf antisense oligodeoxynucleotide in combination with standard chemotherapeutic agents against various human tumors transplanted subcutaneously into nude mice
24. bcl-2 antisense therapy chemosensitizes human melanoma in SCID mice
25. Chemosensitization and delayed androgen-independent recurrence of prostate cancer with the use of antisense Bcl-2 oligodeoxynucleotides
26. Overexpression of Bcl-2 in bladder cancer cells inhibits apoptosis induced by cisplatin and adnoviral-mediated p53 gene transfer
27. Overexpression of Bcl-2 enhances metastatic potential of human bladder cancer cells
28. Cleavage of poly(ADP-ribose) polymerase by a proteinase with properties like ICE
29. Absence of p53 overexpression and favorable response to cisplatin-based neoadjuvant chemotherapy in urothelial carcinomas
30. Synergistic enhancement of resistance to cisplatin in human bladder cancer cells by overexpression of mutant-type p53 and Bcl-2